ScripThe years of effort and expense Abivax has put into advancing obefazimod for ulcerative colitis (UC) have paid off now that the French firm has presented stellar results from a pair of Phase III trial
ScripActuate Therapeutics is looking for a bigger pharma partner to advance its potential first-in-class glycogen synthase kinase-3 beta (GSK-3β) inhibitor elraglusib into later stage cancer trials or comm
ScripHuntington’s disease (HD) has been a notoriously difficult field for drug development but enthusiasm is growing, not least at Skyhawk Therapeutics which has initiated a Phase II/III trial on a potenti
Pink SheetThe European Medicines Agency has started reviewing for potential pan-EU marketing authorization 15 new drugs, including Novo Nordisk’s semaglutide for the treatment of non-cirrhotic metabolic dysfunc